Profits at Irish arm of Roche pharma climb by 17%

Accounts for Roche Products (Ireland) Ltd show that pre-tax profits at the company increased by 17pc to €5.3m in 2023.

The lengthy timelines to reimburse medicines in Ireland must be reduced to improve standards of care and patient outcomes, the directors of the Irish arm of pharma giant Roche have stated.

The directors for Roche Products (Ireland) Ltd make the statement in new accounts which show that pre-tax profits at the Irish operation increased by 17% to €5.3m in 2023. This followed revenues increasing by 7% from €116.3m to €124.68m. The directors report that the company “delivered a solid level of sales growth in 2023”.